Keybank National Association OH reduced its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 12.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,065 shares of the company’s stock after selling 442 shares during the period. Keybank National Association OH’s holdings in IDEXX Laboratories were worth $479,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also modified their holdings of the company. Zions Bancorporation purchased a new position in IDEXX Laboratories during the 3rd quarter valued at about $162,000. Benjamin F. Edwards & Company Inc. lifted its position in IDEXX Laboratories by 1,000.0% during the 4th quarter. Benjamin F. Edwards & Company Inc. now owns 1,100 shares of the company’s stock valued at $172,000 after acquiring an additional 1,000 shares during the period. SignalPoint Asset Management LLC purchased a new position in IDEXX Laboratories during the 4th quarter valued at about $200,000. Ledyard National Bank lifted its position in IDEXX Laboratories by 58.9% during the 4th quarter. Ledyard National Bank now owns 1,295 shares of the company’s stock valued at $203,000 after acquiring an additional 480 shares during the period. Finally, IBM Retirement Fund purchased a new position in IDEXX Laboratories during the 4th quarter valued at about $213,000. 86.02% of the stock is owned by institutional investors.
IDEXX Laboratories, Inc. (IDXX) opened at $187.61 on Monday. The company has a quick ratio of 0.80, a current ratio of 0.97 and a debt-to-equity ratio of -11.26. The stock has a market cap of $16,345.11, a PE ratio of 63.81, a price-to-earnings-growth ratio of 2.31 and a beta of 0.58. IDEXX Laboratories, Inc. has a twelve month low of $141.02 and a twelve month high of $198.73.
In other IDEXX Laboratories news, CEO Jonathan W. Ayers sold 18,000 shares of IDEXX Laboratories stock in a transaction dated Tuesday, January 9th. The shares were sold at an average price of $165.15, for a total value of $2,972,700.00. Following the completion of the transaction, the chief executive officer now directly owns 1,077,112 shares of the company’s stock, valued at $177,885,046.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Giovani Twigge sold 2,000 shares of IDEXX Laboratories stock in a transaction dated Thursday, November 30th. The stock was sold at an average price of $156.07, for a total transaction of $312,140.00. The disclosure for this sale can be found here. Insiders sold 90,762 shares of company stock valued at $15,940,404 over the last ninety days. Corporate insiders own 2.77% of the company’s stock.
A number of brokerages recently issued reports on IDXX. Aegis reissued a “sell” rating on shares of IDEXX Laboratories in a research report on Friday, December 8th. Canaccord Genuity reissued a “buy” rating and set a $210.00 price target on shares of IDEXX Laboratories in a research report on Monday, January 29th. Piper Jaffray Companies began coverage on shares of IDEXX Laboratories in a research report on Tuesday, January 16th. They set an “overweight” rating and a $200.00 price target for the company. Bank of America lifted their price target on shares of IDEXX Laboratories from $200.00 to $220.00 and gave the company a “buy” rating in a research report on Friday, February 2nd. Finally, BidaskClub raised shares of IDEXX Laboratories from a “hold” rating to a “buy” rating in a report on Tuesday, January 16th. One investment analyst has rated the stock with a sell rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $194.00.
TRADEMARK VIOLATION WARNING: This article was originally published by Ticker Report and is the property of of Ticker Report. If you are viewing this article on another publication, it was illegally copied and reposted in violation of United States and international copyright & trademark laws. The original version of this article can be read at https://www.tickerreport.com/banking-finance/3223084/keybank-national-association-oh-sells-442-shares-of-idexx-laboratories-inc-idxx.html.
IDEXX Laboratories Profile
IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.
Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX).
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.